proline and gefitinib

proline has been researched along with gefitinib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
DU, JX; Gong, WX; Huang, SC; Liang, CW; Pan, Y; Peng, DX; Quan, W; Wang, X; Xie, Y; Zhang, N; Zheng, LP	1
Liang, L; Wang, X; Yin, W	1

Other Studies

2 other study(ies) available for proline and gefitinib

Article	Year
[Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2018, May-20, Volume: 38, Issue:5 Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; NF-kappa B p50 Subunit; Proline; Thiocarbamates; Transcription Factor RelA	2018
PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug. Pathology, research and practice, 2022, Volume: 237 Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Co-Repressor Proteins; CTLA-4 Antigen; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glutamates; Humans; Leucine; Lung Neoplasms; Proline; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Transcription Factors	2022

Article

Year

[Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2018, May-20, Volume: 38, Issue:5

Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; NF-kappa B p50 Subunit; Proline; Thiocarbamates; Transcription Factor RelA

2018

PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug.

Pathology, research and practice, 2022, Volume: 237

Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Co-Repressor Proteins; CTLA-4 Antigen; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glutamates; Humans; Leucine; Lung Neoplasms; Proline; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Transcription Factors

2022